CD19 and B-cell non-Hodgkin lymphoma: In patients with B-cell lymphoma treated with CHOP-based chemotherapy containing rituximab, CD19+/CD20+, CD4+, CD3+, CD8+ and CD56+ cells underwent severe depletion during treatment.